1.10 Criticism via Twitter, PACIFIC, PCI for CAD, and Dr. Rebecca Cooney of The Lancet

OncologyMedicineHealth Policy
Written By Kerrington .

Today we tackle some cardiologists' opposition to criticizing clinical trials on Twitter, the PACIFIC trial on durvalumab in stage III non–small-cell lung cancer, and the recent paper in Heart: "Percutaneous Coronary Intervention for Stable Coronary Artery Disease" by R.K. Al-Lamee, A.N. Nowbar, and D.P. Francis. We end with an interview on academic medical publishing with Dr. Rebecca Cooney, North American Executive Editor of The Lancet.

Kerrington .
Previous

1.11 Peanut Gallery, Research Parasites, Appendectomies, HRQoL and PFS, Dr. Bishal Gyawali
Next

1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints